Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label multiple-dose pharmacokinetic study of JNJ-64281802 in healthy adults
NL-OMON51387Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mosnodenvir in dengue fever (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Pharmacokinetics of JNJ-64281802. Started Feb 2022; status: active, not recruiting.
02
Drugs
mosnodenvir
03
Conditions
dengue fever
Beyond the preview
Go deeper on NL-OMON51387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51387.